JP2024524891A5 - - Google Patents
Info
- Publication number
- JP2024524891A5 JP2024524891A5 JP2023576235A JP2023576235A JP2024524891A5 JP 2024524891 A5 JP2024524891 A5 JP 2024524891A5 JP 2023576235 A JP2023576235 A JP 2023576235A JP 2023576235 A JP2023576235 A JP 2023576235A JP 2024524891 A5 JP2024524891 A5 JP 2024524891A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- sequence
- functional variant
- heavy chain
- cytokine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21181271 | 2021-06-23 | ||
| EP21181271.4 | 2021-06-23 | ||
| EP22163748.1 | 2022-03-23 | ||
| EP22163748 | 2022-03-23 | ||
| PCT/EP2022/067236 WO2022268983A2 (en) | 2021-06-23 | 2022-06-23 | Interleukin-15 based immunocytokines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024524891A JP2024524891A (ja) | 2024-07-09 |
| JP2024524891A5 true JP2024524891A5 (enExample) | 2025-06-10 |
Family
ID=82361370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023576235A Pending JP2024524891A (ja) | 2021-06-23 | 2022-06-23 | インターロイキン－１５に基づく免疫サイトカイン |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240294594A1 (enExample) |
| EP (1) | EP4359428A2 (enExample) |
| JP (1) | JP2024524891A (enExample) |
| KR (1) | KR20240024242A (enExample) |
| AU (1) | AU2022296794A1 (enExample) |
| BR (1) | BR112023027312A2 (enExample) |
| CA (1) | CA3221886A1 (enExample) |
| IL (1) | IL309533A (enExample) |
| MX (1) | MX2023015444A (enExample) |
| WO (1) | WO2022268983A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3444271T (pt) | 2013-08-08 | 2022-01-05 | Inst Nat Sante Rech Med | Modulocinas baseadas em il-15 e no domínio sushi de il-15ralfa |
| US20230030674A1 (en) * | 2019-12-06 | 2023-02-02 | Sotio Biotech A.S. | Humanized cldn18.2 antibodies |
| WO2025177263A1 (en) * | 2024-02-25 | 2025-08-28 | Biohaven Therapeutics Ltd. | Myostatin-binding proteins |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI259837B (en) | 1998-05-11 | 2006-08-11 | Eidgenossische Tech Hochscule | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis |
| US20100082438A1 (en) | 2008-10-01 | 2010-04-01 | Ronnie Jack Garmon | Methods and systems for customer performance scoring |
| US20110318302A1 (en) | 2009-01-07 | 2011-12-29 | Kathrin Schwager | Cancer Treatment |
| JP6594855B2 (ja) * | 2013-03-15 | 2019-10-23 | ゼンコア インコーポレイテッド | ヘテロ二量体タンパク質 |
| WO2014174105A1 (en) | 2013-04-25 | 2014-10-30 | Philochem Ag | Antibody-drug conjugates |
| AU2016365114A1 (en) | 2015-11-30 | 2018-05-17 | Abbvie Biotherapeutics Inc. | Anti-huLRRC15 antibody drug conjugates and methods for their use |
| MY203000A (en) * | 2016-10-14 | 2024-06-01 | Xencor Inc | Il15/il15r� heterodimeric fc-fusion proteins |
| MY201482A (en) | 2017-04-03 | 2024-02-26 | Hoffmann La Roche | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 |
| AU2019228381B2 (en) | 2018-02-28 | 2021-12-16 | Pfizer Inc. | IL-15 variants and uses thereof |
| CA3090407A1 (en) * | 2018-03-01 | 2019-09-06 | Glycotope Gmbh | Fusion protein constructs comprising an anti-muc1 antibody and il-15 |
| MA52289A (fr) * | 2018-04-18 | 2021-02-24 | Xencor Inc | Protéines de fusion fc hétérodimères il-15/il-15ra et leurs utilisations |
| AU2019359475A1 (en) * | 2018-10-12 | 2021-05-20 | Xencor, Inc. | PD-1 targeted IL-15/IL-15Ralpha Fc fusion proteins and uses in combination therapies thereof |
| US11738050B2 (en) | 2019-02-01 | 2023-08-29 | Regents Of The University Of Minnesota | Compounds binding to fibroblast activation protein alpha |
| CA3153542A1 (en) * | 2019-09-25 | 2021-04-01 | Leto Laboratories Co., Ltd | Recombinant interleukin-15 analog |
-
2022
- 2022-06-23 WO PCT/EP2022/067236 patent/WO2022268983A2/en not_active Ceased
- 2022-06-23 IL IL309533A patent/IL309533A/en unknown
- 2022-06-23 AU AU2022296794A patent/AU2022296794A1/en active Pending
- 2022-06-23 CA CA3221886A patent/CA3221886A1/en active Pending
- 2022-06-23 KR KR1020247002543A patent/KR20240024242A/ko active Pending
- 2022-06-23 BR BR112023027312A patent/BR112023027312A2/pt unknown
- 2022-06-23 MX MX2023015444A patent/MX2023015444A/es unknown
- 2022-06-23 EP EP22736247.2A patent/EP4359428A2/en active Pending
- 2022-06-23 US US18/573,397 patent/US20240294594A1/en active Pending
- 2022-06-23 JP JP2023576235A patent/JP2024524891A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7698004B2 (ja) | ＦｃγＲＩＩｂ特異的Ｆｃ領域改変体 | |
| JP7245815B2 (ja) | 改変されたＦｃ領域を含む抗原結合分子 | |
| JP2024524891A5 (enExample) | ||
| US11820793B2 (en) | Drug containing carrier into cell for forming immune complex | |
| US20220389118A1 (en) | Antigen-binding molecule for promoting elimination of antigens | |
| US20240317858A1 (en) | Anti-cd3 antibodies | |
| JP2023106564A (ja) | 抗原結合分子の血漿中滞留性と免疫原性を改変する方法 | |
| JP2026041927A (ja) | Ｆｃ領域改変体 | |
| JP2020124209A (ja) | Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体 | |
| JP2022033769A (ja) | 強化されたアゴニスト活性を有する、Ｆｃが遺伝子操作を受けた抗ＴＮＦＲスーパーファミリーメンバー抗体及びその使用方法 | |
| JP2024534454A5 (enExample) | ||
| JP2017165728A (ja) | 強化又は抑制されたエフェクター機能を有する抗体 | |
| AU2012233313A1 (en) | Method for altering plasma retention and immunogenicity of antigen-binding molecule | |
| US20230365641A1 (en) | Targeted cytokines and methods of use thereof | |
| MX2014010140A (es) | Molecula de union al antigeno para promover la perdida de antigeno a traves de fc?riib. | |
| JP2023541816A5 (enExample) | ||
| JP2023523016A5 (enExample) | ||
| AU2023363979A1 (en) | Ph-dependent anti-cd3 antibodies and methods relating thereto | |
| WO2023010098A2 (en) | Novel multi-specific molecules | |
| WO2025245176A1 (en) | Multispecific antibody constructs | |
| RU2820161C1 (ru) | СПОСОБ ПОЛУЧЕНИЯ ВАРИАНТОВ FcyRIIB-СПЕЦИФИЧЕСКОЙ Fc-ОБЛАСТИ | |
| RU2799423C1 (ru) | Способ изменения удержания в плазме и иммуногенности антигенсвязывающей молекулы | |
| HK1215034B (zh) | Fc区变体 |